These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 3312022)

  • 21. Nosocomial spread of ceftazidime-resistant Klebsiella pneumoniae strains producing a novel class a beta-lactamase, GES-3, in a neonatal intensive care unit in Japan.
    Wachino J; Doi Y; Yamane K; Shibata N; Yagi T; Kubota T; Ito H; Arakawa Y
    Antimicrob Agents Chemother; 2004 Jun; 48(6):1960-7. PubMed ID: 15155185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative in-vitro activities of newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime- or imipenem-resistant Pseudomonas aeruginosa.
    Watanabe N; Hiruma R; Katsu K
    J Antimicrob Chemother; 1992 Nov; 30(5):633-41. PubMed ID: 1493980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitor-sensitive AmpC beta-lactamase variant produced by an Escherichia coli clinical isolate resistant to oxyiminocephalosporins and cephamycins.
    Doi Y; Wachino J; Ishiguro M; Kurokawa H; Yamane K; Shibata N; Shibayama K; Yokoyama K; Kato H; Yagi T; Arakawa Y
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2652-8. PubMed ID: 15215122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.
    Papp-Wallace KM; Bajaksouzian S; Abdelhamed AM; Foster AN; Winkler ML; Gatta JA; Nichols WW; Testa R; Bonomo RA; Jacobs MR
    Diagn Microbiol Infect Dis; 2015 May; 82(1):65-9. PubMed ID: 25737290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo selection of a complex mutant TEM (CMT) from an inhibitor-resistant TEM (IRT) during ceftazidime therapy.
    Jacquier H; Marcadé G; Raffoux E; Dombret H; Woerther PL; Donay JL; Arlet G; Cambau E
    J Antimicrob Chemother; 2013 Dec; 68(12):2792-6. PubMed ID: 23861309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro selection and characterization of mutants in TEM-1-producing Escherichia coli by ceftazidime and ceftibuten.
    Perilli M; Segatore B; Tavio M; Setacci D; Celenza G; De Santis F; Pellegrini C; Rossolini GM; Amicosante G
    J Chemother; 2007 Apr; 19(2):123-6. PubMed ID: 17434819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of a plasmid coding for resistance to broad-spectrum cephalosporins in Salmonella typhimurium.
    Garbarg-Chenon A; Vu Thien H; Labia R; Ben-Yaghlane H; Godard V; Deny P; Bricout F; Nicolas JC
    Drugs Exp Clin Res; 1989; 15(4):145-50. PubMed ID: 2673714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A novel extended-spectrum beta-lactamase in a ceftazidime-resistant isolate of E. coli].
    Cheng Y; Li Y; Chen M
    Wei Sheng Wu Xue Bao; 1994 Oct; 34(5):360-6. PubMed ID: 7871780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel plasmid-mediated beta-lactamase from Escherichia coli that inactivates oxyimino-cephalosporins.
    Matsumoto Y; Ikeda F; Kamimura T; Yokota Y; Mine Y
    Antimicrob Agents Chemother; 1988 Aug; 32(8):1243-6. PubMed ID: 3056257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased expression levels of chromosomal AmpC β-lactamase in clinical Escherichia coli isolates and their effect on susceptibility to extended-spectrum cephalosporins.
    Paltansing S; Kraakman M; van Boxtel R; Kors I; Wessels E; Goessens W; Tommassen J; Bernards A
    Microb Drug Resist; 2015 Feb; 21(1):7-16. PubMed ID: 25188329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitory activity of avibactam against selected β-lactamases expressed in an isogenic Escherichia coli strain.
    Giani T; Cannatelli A; Di Pilato V; Testa R; Nichols WW; Rossolini GM
    Diagn Microbiol Infect Dis; 2016 Sep; 86(1):83-5. PubMed ID: 27394638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Escherichia coli resistant to ampicillin/sulbactam.
    Eng RH; Yen K; Smith SM; Citron DM; Goldstein EJ; Greenberg R; Cherubin CE
    Chemotherapy; 1992; 38(6):399-404. PubMed ID: 1288964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Previous Antibiotic Exposure Increases Risk of Infection with Extended-Spectrum-β-Lactamase- and AmpC-Producing Escherichia coli and Klebsiella pneumoniae in Pediatric Patients.
    Zerr DM; Miles-Jay A; Kronman MP; Zhou C; Adler AL; Haaland W; Weissman SJ; Elward A; Newland JG; Zaoutis T; Qin X
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4237-43. PubMed ID: 27139486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Separation of plasmid-mediated extended spectrum beta-lactamases by fast protein liquid chromatography (FPLC system).
    Payne DJ; Hood J; Marriott MS; Amyes SG
    FEMS Microbiol Lett; 1990 Jun; 57(3):195-200. PubMed ID: 2210330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective ceftazidime resistance in Escherichia coli: association with changes in outer membrane protein.
    Bakken JS; Sanders CC; Thomson KS
    J Infect Dis; 1987 Jun; 155(6):1220-5. PubMed ID: 3553348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
    Bethel CR; Hujer AM; Helfand MS; Bonomo RA
    FEMS Microbiol Lett; 2004 May; 234(1):99-103. PubMed ID: 15109726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The effect of cefepime on ceftazidime, cefotaxime and imipenem resistant strains of Acinetobacter, Xanthomonas, Pseudomonas, Flavobacterium, Sphingobacterium and on producers of extended spectrum beta-lactamases (ESBL) with resistance transfer].
    Blahová J; Hupková-Lesická M; Králiková K; Krcméry V; Kubonová K
    Cas Lek Cesk; 1997 Mar; 136(5):154-6. PubMed ID: 9221190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structures of ceftazidime and its transition-state analogue in complex with AmpC beta-lactamase: implications for resistance mutations and inhibitor design.
    Powers RA; Caselli E; Focia PJ; Prati F; Shoichet BK
    Biochemistry; 2001 Aug; 40(31):9207-14. PubMed ID: 11478888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-level resistance to ceftazidime conferred by a novel enzyme, CTX-M-32, derived from CTX-M-1 through a single Asp240-Gly substitution.
    Cartelle M; del Mar Tomas M; Molina F; Moure R; Villanueva R; Bou G
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2308-13. PubMed ID: 15155242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic utility of boronic acid inhibition with different cephalosporins against Escherichia coli producing AmpC β-lactamases.
    Upadhyay S; Sen MR; Bhattacharjee A
    J Med Microbiol; 2011 May; 60(Pt 5):691-3. PubMed ID: 21292860
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.